1. Home
  2. FSLY vs PHVS Comparison

FSLY vs PHVS Comparison

Compare FSLY & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fastly Inc.

FSLY

Fastly Inc.

N/A

Current Price

$20.69

Market Cap

2.7B

Sector

Technology

ML Signal

N/A

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

N/A

Current Price

$35.43

Market Cap

2.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FSLY
PHVS
Founded
2011
2015
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.4B
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
FSLY
PHVS
Price
$20.69
$35.43
Analyst Decision
Hold
Buy
Analyst Count
8
11
Target Price
$18.00
$41.82
AVG Volume (30 Days)
5.5M
617.5K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
27.19
N/A
EPS
N/A
N/A
Revenue
$624,018,000.00
N/A
Revenue This Year
$16.39
N/A
Revenue Next Year
$10.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
14.78
N/A
52 Week Low
$7.74
$20.65
52 Week High
$34.82
$38.13

Technical Indicators

Market Signals
Indicator
FSLY
PHVS
Relative Strength Index (RSI) 42.90 52.36
Support Level $19.81 $24.55
Resistance Level $21.99 $36.36
Average True Range (ATR) 1.74 1.45
MACD -0.72 -0.18
Stochastic Oscillator 13.14 43.19

Price Performance

Historical Comparison
FSLY
PHVS

About FSLY Fastly Inc.

Fastly Inc is a cloud computing company that provides an edge cloud platform designed to deliver, secure, and optimize digital experiences over the internet. The company operates a unified platform that combines content delivery, edge computing, and security capabilities. Its services include content delivery networks, web and API protection, distributed denial of service mitigation, and real-time data processing at the edge. Its platform enables customers to improve the performance, scalability, and security of applications and digital content, and also supports cloud-native architectures, AI-driven workloads, and programmable edge computing solutions.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.

Share on Social Networks: